Trials / Terminated
TerminatedNCT03329885
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly rash).
Conditions
- Rheumatoid Arthritis
- Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Diseases
- Nonalcoholic Steatohepatitis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986251 | Escalating oral dose |
| OTHER | Placebo | Escalating oral dose |
Timeline
- Start date
- 2017-11-02
- Primary completion
- 2018-06-26
- Completion
- 2018-06-26
- First posted
- 2017-11-06
- Last updated
- 2019-10-21
- Results posted
- 2019-10-21
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03329885. Inclusion in this directory is not an endorsement.